We analyzed soluble vascular adhesion molecules (sVCAM-l), reactive oxygen metabolites (ROMs) level, total antioxidant status (TAS) and telediastolic left ventricular volume (TLVV) in patients with myocardial infarction undergoing reperfusion therapy and treated with antioxidant vitamins (AT) or placebo (P) before and for 1 month after reperfusion. After reperfusion, sVCAM-l serum concentration, reactive oxygen metabolites level, and TLVV were significantly higher in patients treated with placebo than in those treated with antioxidant vitamins, while TAS was significantly higher in patients treated with antioxidant supplementation. We observed that 48 hours after reperfusion sVCAM-l (P) vs sVCAM -l(AT) was 2.03±O.5 vs 1.63±O.7 ug/ml with p<O.Ol; ROMs (P) vs ROMs (AT) were 335.60±35.80 vs 307.50±47.10 V.CARR with p<O.05; TAS (P) vs TAS (AT) was 526.47±44.24 vs 737.65±51.15 umol/l with p<O.Ol; 1 week after reperfusion TLVV (P) vs TLVV (AT) was 125.12±29.80vs 119.40±29.40 ml with p<O.05; 1 month after reperfusion TLVV (P) vs TLVV (AV) was 132.00±33.50 vs 123.40±21.60 ml with p<O.05. In the first period after infarction, vitamin treatment improves the antioxidant system and reduces oxidative stress, inflammatory process and left ventricular remodeling.
myocardium named remodeling. These changes can contribute to the development of heart failure, reinfarction, arrhythmia, and sudden cardiac death. Recent evidence has suggested a link between ROS and the development of myocardial remodeling and failure (13) (14) 23) . Endothelial activation and oxidative stress seem to be linked to the LV remodeling, and the aim of this study was to see if antioxidant therapy affects adhesions endothelial property and ROS production in the first phase of AMI and to investigate whether the modulation of ROS and adhesion molecules by antioxidant therapy can affect ventricular remodeling. So, we analyzed soluble VCAM-l, ROS level and total antioxidant status (TAS) in patients with AMI undergoing reperfusion therapy (thrombolysis or angioplasty) and treated with antioxidant vitamins (vitamin C, E and A) or placebo, before and for 1 month after reperfusion, and we compared these results with the LV dilatation.
The antioxidant properties of vitamin C (24) and E (25) are well known, and it has been proposed that also vitamin A may have antioxidant properties (26) , but it is uncertain if vitamin A itself can exert these properties (27) . However, vitamin A can affect the tissue levels of other antioxidants such as atocopherol and selenium (27) , and act as an antiinflammatory agent (28) .
ROS are very reactive and short-lived, so their direct detection is difficult. Determination of lipoperoxides (LPOs), total antioxidant status (TAS), and nitric oxide end products is very important in determining the effects of free radicals in biological systems (29) . On the other hand, a technique designed to measure reactive oxygen species should be: a) specific, b) very sensitive, c) not requiring expensive or complicated laboratory equipment, and d) easy to standardize. Up to now, no technique has been found to satisfy all this criteria (30) .
MATERIALS AND METHODS
We enrolled 98 patients (25 female and 73 male; age: from 40 to 86), with diagnosis of acute myocardial infarction (AMI), undergoing reperfusion therapy (thrombolysis or angioplasty) in accordance with the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-I) study (31) . Patients were randomly double blind selected to receive normal therapy plus antioxidant supplementation (Group AT, 49 patients) or normal therapy plus placebo (Group P, 49 patients).
The antioxidant therapy followed the following scheme:
Before reperfusion: Vitamin C, 1 gin i.v. bolus. After reperfusion, every day for 1 month: Vitamin C, I g daily, Vitamin A 50.000 Unit daily and Vitamin E, 300 mg daily orally.
Informed consent was obtained from all patients, and the local Ethics Committee approved the study protocol. Blood samples from all patients were taken immediately before reperfusion (Oh), 48 hours and 1 month after therapy (follow up, FU). Serum samples were obtained and stored at -80°C until use. All assays were performed within 6 month from collection. Levels ofROS, sVCAM-1 and TAS were analyzed. To determine the ROS levels, we used the d-ROM test (Diacron srl, Grosseto, Italy). In this assay, the amount of organic hydroperoxydes in a biological sample is related to the free radicals from which they are formed (32) . While the assay with thiobarbituric acid and malondialdheyde measure later markers of oxidative stress, the hydroperoxydes, formed from proteins, lipids, peptides and other biological molecules, are the first ROS present during the oxidative process (29) .
When the sample is dissolved in an acidic buffer, the hydroperoxydes react with the transition metal ions derived from the proteins in the acidic medium and are converted in alkoxy and peroxy radicals (33) . These radicals are able to oxidize the additive N,N-dyethyl-paraphenyl-diammine present in the Cromogen Buffer, to the corresponding radical cation. The concentration of this stable radical species can be determined at 505 nm with a spectrophotometer. Results are expressed in arbitrary conventional unit, named U.CARR (Carratelli Units) and 1 U.CARR=0.08mg% oxygen peroxide. The normal value is 250-300 U.CARR, and over this result we have oxidative stress. The method is considered specific and sensitive: within run variation was less than 2.6% and between-run variation less than 4.6% (32) .
Briefly, 5 ul of samples, standard or water (blank) were incubated (l00 min., 37°C) with 1 ml ofCromogen Buffer and the optical density was read at 505 nm with a spectrophotometer (Beckman DU 640). Data were obtained from the following formula: OD sample/OD standard x Standard Concentration = U.CARR The TAS was measured using a Med.Dia® kit based on the principle that antioxidant level in sample is detected by evaluation of Cu+ derived from Cu++ by action of all antioxidants present. The determination ofCu+ is detected with the evaluation of the formation of Cu+ and bathocuproine complex. This complex is stable and has a typical absorption at 480-490 run. The evaluated values are compared with a standard curve obtained by the sample to a known concentration of uric acid used as a typical reducing agent. The test validation, performed to evaluate the correlation with antioxidant concentration (ascorbic acid, vitamin E, glutathione), has given a correlation coefficient of R=O.804. sVCAM-l serum concentration was analysed using a commercial double primary antibody sandwich ELISA (Bender MedSystem, Vienna, Austria). Data are presented as mean ± standard error. Differences between placebo and antioxidant treated patients were evaluated with the non-parametric Mann-Whitney test. values are significant for p<O.05.
RESULTS
Before reperfusion and therapy (Oh), all patients showed similar values of telediastolic left ventricular volume (TLVV), sVCAM-l, ROS and TAS. (Table 1 -IV, Fig. 1-4 ). After 48 hours, in patients treated with placebo (P), sVCAM-l and ROS levels were higher than the ones in patients treated with antioxidant vitamins (AT) (p<O.OI and p<0.05, respectively), while TAS were significantly higher in AT versus P (p<O.OI). (Table I -III, Fig. 1-3 ). After 1 week the TLVV was higher in patients treated with placebo than in patients treated with antioxidants (p<0.05). (Table IV, Fig. 4 ). After 1 month (follow-up) there was no difference in sVCAM-l, ROS and TAS between AT and P, while the TLVV volume was higher in P versus AT (p<0.05). (Table I -IV, Fig. 1-4 ).
We found an enhanced level of ROMs and sVCAM-l in patients treated only with the conventional therapy and placebo, confirming that reperfusion after ischaemia plays an important role in the activation of the inflammatory process. Patients treated with reperfusion therapy and antioxidants showed equal levels of ROMs and sVCAM-l before and 48 hours after the reperfusion. In this case the reperfusion did not enhance the activation of the inflammatory process. In the first hours after the AMI, a second heart attack and arrhythmias represent the most common complications, and they are strictly related to the activation of endothelium, platelet and neutrophils due to the ischemic damage but enhanced by reperfusion. Arrhythmias are often related to cellular suffering, with alteration of the membrane potential, resulting from ischaemia but also from ROMs damage. Our data suggest that antioxidant therapy can reduce, in the first period after AMI, the oxidative stress and the inflammatory process, and can affect remodeling. The two groups of patients showed a different outcome in relation to the dilatation of the left ventricle: patients in the placebo group had higher dilatation of the left ventricle respect to the patients treated with antioxidant vitamins. These data are significant after 1 week and also during the follow-up period.
DISCUSSION
Data in the literature concerning the effects of antioxidant supplementation in patients with cardiovascular disease are discordant. In 1993 researchers from India studied the correlation between antioxidant substances and clinical aspects of cardiovascular disease in the Indian population. The normal Indian diet is rich in onions, garlic, gooseberries, mushrooms, hazel-nut, vegetables, sunflower seed oil, soya seeds, almonds, walnuts etc. that can modulate lipid plasma concentration and fibrinolytic activity, reducing the atherosclerotic process. In this randomized study, 505 patients with AMI followed different dietary regimens in the 3 years after surviving a stroke. A diet rich in fibres, minerals and antioxidant vitamins reduced the death rate after one year (35) .
In the "Supplementation en Vitamines et Mineraux AntioXydants" (SU.VI.MAX), a doubleblind, placebo-controlled, primary-prevention trial, 12735 healthy subjects were enrolled to see if daily supplementation with antioxidant vitamins (vitamin C, 120 mg, vitamin E, 30 mg, and beta-carotene, 6 mg) and minerals (selenium, 100 microg, and zinc, 20 mg), could reduce the main causes of premature death (cancers and cardiovascular diseases). After 2 years of supplementation, biochemical indicators of vitamin and trace element status tested relatively high doses of antioxidants, and ended up with a higher risk of the disease (36 (36) . The U.S. Nurses' Health Study suggests that among middleaged women the use of vitamin E is associated with a dose-dependent reduced risk of coronary heart disease (38) .
In the year 2000, the Heart Outcomes Prevention Evaluation Study Investigators, a double-blind randomised study, 9541 patients with a history of coronary artery disease, stroke, peripheral artery disease, hypertension and diabetes were enrolled to test the effect of high doses of vitamin E supplementation. The primary outcome was a composite of myocardial infarction, stroke and death from cardiovascular disease. The secondary outcome included unstable angina, congestive heart failure, revascularization or amputation, death from any cause, complication of diabetes and cancer. In patients at high risk for cardiovascular events, vitamin E had no apparent effect on cardiovascular disease, after 4-5 years (39) .
Natural and synthetic antioxidant can stop lipid peroxydation and prevent free radical formation by intercepting the intermediate oxygen metabolites. Vitamin C is a potent reducing agent and plays an important antioxidant role in plasma membrane and within cell (24) . It is oxidised in two steps, first to ascorbyl radical, and then to dehydroascorbate, with the release of two hydrogen atoms. Hydrogen atoms react in plasma with the peroxyl radical (AOO') derived from a radical-initiator (2,2' -azobis-(2aminopropane) dihydrochloride or AAPH) present in plasma, to form a non radical product, AOOH, the AAPH-derived hydroperoxide. AOO' trapping prevents LDL and lipoprotein oxidation in plasma (40) (41) (42) .
Like vitamin C, vitamin E is a hydrogen donor. Its antioxidant properties are related to its chemical structure. Vitamin E is localised in membrane plasma and can interrupt the radical chain reaction of lipid peroxydation because it is able to scavenge free radicals by donating its phenolic hydrogen atom to a fatty acyl or oxygen free radical species, preventing their propagation (43) .
The hydrophobic chain of polyene units that can quench singlet oxygen, neutralize radicals and combine with and stabilize peroxyl radicals, confers the antioxidant activity of vitamin A and carotenoids. The antioxidant properties are related to the polyene chain length, and carotenoids have an antioxidant capacity higher than vitamin A. The scavenging of peroxyl radical by beta-carotene and vitamin A occurs efficiently only at low 02 tensions, whereas at ambient 02 tensions may exert prooxidant activity (26) . Therefore, we must consider that vitamins are redox agents and give protection from free radicals, but they can also induce lipid peroxydation. Vitamins at physiological concentrations are present in cells and plasma in reducing and/or oxidising mode, while in pharmacological supplementation antioxidants are only in reducing state, and they could enhance free radical formation. This hypothesis could explain the antioxidant trial controversy.
In conclusion our data suggest that antioxidant therapy can reduce, in the first period after AMI, the oxidative stress, the inflammatory process, and the remodeling ofleft ventricle and can affect the rate of a second heart attack in the short term. On the other hand a chronic therapy with antioxidants seems to have no effects on the prevention of the oxidative stress in the long term. This observation could be related to a different way of administration (intravenously in the acute period, orally in the following month) but also to an accumulation of vitamins, with possible pro-oxidative effects.
